Zedira Presents Clinical Candidate for Celiac Disease Therapy
Advertisement
In course of the Chicago celiac disease Conference preclinical data has been presented supporting the selection of Zedira’s novel Transglutaminase blocker ZED-101 as clinical candidate for the treatment of celiac disease.
Blocking tissue transglutaminase is a promising therapeutic option in celiac disease. Zedira developed rationally designed peptidomimetic blockers bearing a michael acceptor pharmacophore. The safety profile and selectivity over other transglutaminase isoenzymes make ZED-101 an optimal candidate for subsequent clinical development.
Zedira considers either out-licensing ZED-101 to a pharmaceutical company or further conducting preclinical and clinical trials backed by investors.